Protalix BioTherapeutics Issues 2025 Letter to Stockholders - PR Newswire

Protalix BioTherapeutics announces significant milestones in 2024, including EMA validation for a less frequent dosing regimen for Fabry disease, progress in PRX-115 clinical trials, and repayment of all outstanding convertible notes, positioning the company for long-term growth.


Related News

Protalix BioTherapeutics Issues 2025 Letter to Stockholders - PR Newswire

Protalix BioTherapeutics announces significant milestones in 2024, including EMA validation for a less frequent dosing regimen for Fabry disease, progress in PRX-115 clinical trials, and repayment of all outstanding convertible notes, positioning the company for long-term growth.

© Copyright 2024. All Rights Reserved by MedPath